Exploring Novel Schiff Base Compounds Derived from Benzothiophene-3- carboxaldehyde Hydrazones: In vitro and In silico Evaluation as Potential Inhibitors of Cholinesterases and Carbonic Anhydrases I-II

Abstract

In this study, inhibitions of some cytosolic enzymes were evaluated. Inhibitors of these enzymes can help illuminate and treat many related diseases (Alzhaimer, Parkinson's, Glaucoma, etc.). It is aimed to minimize drug side effects with multiple effects in one molecule. For this purpose in vitro effects of two benzothiophene Schiff bases on cholinesterases (AChE and BuChE) and human carbonic anhydrase isoforms (CAI and CAII) were investigated. Molecular modeling studies were carried out to elucidate the inhibition mechanism of two effective compounds on these enzymes. Then, two benzothiophene Schiff bases (1a and 1b compounds) were tested in vitro on these enzymes. The in vitro study results supported the in silico study results. Obtained results revealed that the benzothiophene derivatives inhibited the enzymes significantly. Ki values for CAI isoenzyme were determined to be in the range of 58.82 ± 7.96-126.28 ± 26.22 nM; for the CAII isoenzyme in the range of 27.86 ± 3.76-74.30 ± 7.89 nM; for acetylcholinesterase in the range of 1.31 ± 0.39-2.16 ± 1.01 nM; for butyrylcholinesterase in the range of 1.80 ± 0.27-2.01 ± 1.67 nM. Compared to the AZA control compound, 1b has demonstrated more strong inhibitory effect against CAI and CAII. Wherease compared with other control compound Tacrine, both compounds showed more potent inhibitory effect for cholinesterases (AChE and BuChE).